14.64

7.01% -1.06

Arcus Biosciences Inc (RCUS)

Overview News Price History Option Chain Why RCUS Down? Discussions Forecast

Arcus Biosciences Inc stock is traded at $14.64, with a volume of 367.52K. It is down -7.01% in the last 24 hours and down -20.82% over the past month. Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.

Previous Close:

$15.70

Open:

$15.49

24h Volume:

367.52K

Relative Volume:

0.53

Market Cap:

$1.38B

Revenue:

$247.00M

Net Income/Loss:

$-249.00M

P/E Ratio:

-3.697

EPS:

-3.96

Net Cash Flow:

$-267.00M

1W Performance:

-17.75%

1M Performance:

-20.82%

6M Performance:

-13.61%

1Y Performance:

+0.76%

1-Day Range:

$14.41

$15.73

1-Week Range:

$14.41

$17.76

52-Week Range:

$13.49

$20.31

Arcus Biosciences Inc Stock (RCUS) Company Profile

Name

Arcus Biosciences Inc

Sector

Healthcare (1200)

Industry

Biotechnology (682)

Phone

(510) 694-6200

Address

3928 POINT EDEN WAY, HAYWARD, CA

Employee

577

Twitter

@arcusbio

Next Earnings Date

2024-12-06

Latest SEC Filings

RCUS's Discussions on Twitter

Compare RCUS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RCUS	14.63	1.38B	247.00M	-249.00M	-267.00M	-3.96
VRTX	467.20	119.83B	10.63B	-479.80M	-1.35B	13.33
REGN	760.34	83.28B	13.85B	4.65B	3.32B	35.06
ARGX	565.93	33.74B	1.86B	-40.29M	-1.28B	-4.16
ALNY	230.51	30.38B	2.09B	-332.26M	16.06M	-4.14
BNTX	101.13	24.08B	3.30B	-501.07M	1.03B	11.54

Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-21-24	Initiated	H.C. Wainwright	Neutral
Oct-08-24	Initiated	Wells Fargo	Overweight
Nov-18-22	Initiated	BofA Securities	Neutral
Oct-11-22	Initiated	Morgan Stanley	Overweight
Oct-15-21	Resumed	BTIG Research	Buy
Nov-24-20	Initiated	Berenberg	Buy
Nov-23-20	Initiated	Evercore ISI	Outperform
Apr-03-20	Initiated	Cantor Fitzgerald	Overweight
Mar-04-20	Initiated	Barclays	Overweight
Nov-12-19	Initiated	SunTrust	Buy
Sep-27-19	Initiated	Mizuho	Buy
May-24-19	Resumed	Citigroup	Buy
Oct-09-18	Initiated	Wedbush	Outperform
Apr-09-18	Initiated	Citigroup	Buy
Apr-09-18	Initiated	Goldman	Neutral
Apr-09-18	Initiated	Leerink Partners	Outperform

View All

Arcus Biosciences Inc Stock (RCUS) Latest News

Nov 13, 2024

Arcus Biosciences' SWOT analysis: biotech stock faces pivotal data releases - Investing.com

Nov 13, 2024

Arcus Biosciences' SWOT analysis: biotech stock faces pivotal data releases By Investing.com - Investing.com UK

Nov 13, 2024

FMR LLC Bolsters Stake in Arcus Biosciences Inc - GuruFocus.com

Nov 13, 2024

Nov 12, 2024

Arcus Biosciences Awards Key Equity Grants to New Hires at $17.85 Per Share | RCUS Stock News - StockTitan

Nov 12, 2024

GSA Capital Partners LLP Raises Stock Holdings in Arcus Biosciences, Inc. (NYSE:RCUS) - MarketBeat

Nov 12, 2024

Nov 11, 2024

FY2024 Earnings Forecast for RCUS Issued By HC Wainwright - MarketBeat

Nov 11, 2024

Nov 09, 2024

Analysts Have Made A Financial Statement On Arcus Biosciences, Inc.'s (NYSE:RCUS) Third-Quarter Report - Yahoo Finance

Nov 09, 2024

Nov 08, 2024

Arcus Biosciences, Inc. (NYSE:RCUS) Q3 2024 Earnings Call Transcript - MSN

Nov 08, 2024

Nov 07, 2024